Bicara Therapeutics (BCAX) Non-Current Assets (2023 - 2026)

Bicara Therapeutics (BCAX) has 4 years of Non-Current Assets data on file, last reported at $8.7 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 18.59% year-over-year to $8.7 million; the trailing twelve-month figure through Mar 2026 stood at $154.1 million (up 657.28% YoY), and the FY2025 full-year result was $8.9 million, up 19.8% from the prior year.
• Non-Current Assets for Q1 2026 stood at $8.7 million, down from $8.9 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $127.3 million in Q3 2025 and bottomed at $2.7 million in Q3 2024.
• The 4-year median for Non-Current Assets is $8.1 million (2024), against an average of $21.8 million.
• The widest annual swing landed in 2025, when Non-Current Assets surged 4688.12%; it then rose 18.59% in 2026.
• A 4-year view of Non-Current Assets shows it stood at $2.9 million in 2023, then soared by 156.55% to $7.5 million in 2024, then grew by 19.8% to $8.9 million in 2025, then declined by 2.87% to $8.7 million in 2026.
• The last three Non-Current Assets figures came in at $8.7 million (Q1 2026), $8.9 million (Q4 2025), and $127.3 million (Q3 2025), per Business Quant data.

Peer Comparison